Phacilitate Leaders World

Conference speakers

Loading
Isaac Erickson

Isaac Erickson

Senior Program Manager, DiscGenics Inc.

Isaac Erickson joined DiscGenics to manage the regulatory efforts in Japan leading to the successful acceptance of a Clinical Trial Notification (CTN).  He also developed and directs the logistics network in support of both domestic and foreign clinical trials.  In addition, Isaac is leading the process engineering group in assessing and implementing technology for successful transfer to DiscGenics’ new manufacturing site.  Previous to DiscGenics, Isaac cultivated extensive experience in using sodium hyaluronate hydrogels for tissue engineering and stem cell delivery at both the University of Pennsylvania and at BioTime.  Altogether, Isaac has spent nearly 15 years in the fields of sodium hyaluronate and regenerative medicine producing academic publications, developing new products, supporting clinical trials, and establishing new technology.

Sessions
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK